Cytokines and their antagonists as therapeutic agents

Liljana Stevceva1

  • 1Thomas Jefferson Medical College, Department of Pathology, Anatomy and Cell Biology, Philadelphia, PA 19107, USA. Liljana.Stevceva@mail.tju.edu

Current Medicinal Chemistry
|December 10, 2002
PubMed

Cytokines are powerful molecules that the body's immune cells secrete in response to an offending agent. Their main function is to direct the immune response into the most effective pathway that will eventually result in elimination of the offender. The last decade was marked by an enormous and ever growing interest that led to discovery of numerous cytokine molecules and their amazing influence on the body immune function. The more we are learning about the way cytokines modulate and direct the immune responses of the body, the interest in using them or their antagonist to change or enhance those responses is growing. Studies are currently underway showing the beneficial effect of TNFalpha antagonists on the cellular injury mediated by this cytokine in rheumatic diseases, inflammatory bowel disease and endotoxemia. Interferon therapies are also tested utilizing IFNalpha for treatment of Hepatitis B and C. The discovery of Th1 and Th2 cytokines had shown that the nature of the immune response is, in essence, directed by a few important cytokines. Which immune reactions will develop seems to depend on whether IL-2 and IL-12 are secreted (and the immune response becomes Th1 with secretion of IFNgamma and efficient removal of some antigens such as viruses) or IL-4 is secreted in which case Th2 response results in down regulation of IFNgamma and IL-2 secreting effectors. The discovery, isolation and purification of these molecules open the possibility to skew the immune response in order to facilitate better outcome. For example, studies have now being conducted aimed at using IL-2 as an adjuvant therapy in conjunction with HAART in HIV patients. Similarly, IL-12 seems to be beneficial in melanoma and has been used as a very potent adjuvant for eliciting immune responses to immunization. Furthermore, studies with IL-4 knockout mice and those utilizing IL-4 blocking agents have shown that this cytokine might play a crucial role in maintaining persistent viral infections and in mediating chronic, autoimmune diseases. Using body's own immunomodulators is becoming an exciting possibility to target inefficient or misdirected immune responses that result in disease. The potential benefits in terms of human disease are enormous and still largely unexplained. Thus, using cytokines and their antagonists as therapeutic agents is an emerging and growing area of research.

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...